Results 71 to 80 of about 18,044 (238)

Addressing challenges for sustainable healthcare in Central and Eastern Europe [PDF]

, 2016
All European countries face increasing challenges in the provision of equitable and comprehensive healthcare for their citizens in view of a number of factors including changing demographics and the launch of new premium priced medicines.
Godman, Brian, Haycox, Alan, Martin, Antony Paul, Novakovic, Tanja, Ootwijn, Wija, Parker, Mark, Tesic, Danka   +6 more
core   +3 more sources

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars

Frontiers in Pharmacology
The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs.
Zhen Zeng, Zhen Zeng, Zhen Zeng, Hao Lin, Hao Lin, Hao Lin, Mingshan Jiang, Mingshan Jiang, Mingshan Jiang, Jing Yuan, Jing Yuan, Jing Yuan, Xi Li, Xi Li, Yongbin Jia, Li Yang, Hu Zhang, Hu Zhang, Hu Zhang   +18 more
doaj   +1 more source

Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic

BMC Health Services Research, 2023
Background Knowledge, attitudes and substitution laws of biosimilars are not consistent across countries. Biosimilar acceptance among patients and healthcare professionals may be suffering from gaps in knowledge and understanding about biosimilars and ...
Kirstin Messner, Christiane Eickhoff, Martin Schulz, Samuel S. Allemann, Isabelle Arnet   +4 more
doaj   +1 more source

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, EarlyView.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]

, 2017
Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source